Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.

ABSTRACT: Combining immunotherapy with chemoradiation is effective in locally advanced cervical cancer. However, the impact of induction combination immunotherapy on immune modulation and treatment response is poorly understood. In this phase II trial (NCT04256213), 40 females with locally advanced cervical carcinoma received one cycle of nivolumab-plus-ipilimumab immunotherapy before standard chemoradiation, followed by maintenance nivolumab. We show, using multiplex-immunofluorescence tissue imaging, a significantly increased CD8⁺/FOXP3⁺ cell ratio (primary endpoint; increase of 0.87 cells/mm², P = 0.0164) and proliferative CD8⁺ T-cell density after one cycle of combination immunotherapy. HOT score (27-gene-based signature identifying immunologically active tumors)

SUBMITTER: Ray-Coquard I 

PROVIDER: S-EPMC12830898 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature